Podcasts about mras

Joining the Project Purple Podcast is Andrew Waters, PhD, Assistant Professor of Medical Surgical Oncology at the University of Cincinnati. Dr. Waters joins host Dino Verrelli to discuss his lab's recent research recovery grant from Project Purple and his journey into pancreatic cancer research. Dr. Waters discusses the critical role of KRAS mutations that are found in about 93-94% of pancreatic cancer cases. KRAS and RAS-targeted therapies have evolved from being considered “undruggable” to becoming one of the most exciting and progressive areas in cancer treatment. Recent clinical breakthroughs include promising results from RevMed's investigational drug Daraxonrasib, which targets multiple KRAS mutations and has demonstrated early trial outcomes. We learn about the challenges that remain in pancreatic cancer research, including complex FDA approvals and access to use. Dr. Waters highlights his lab's research into how pancreatic cancer cells develop resistance to KRAS inhibitors by leveraging related proteins such as HRAS. NRAS and MRAS. Understanding these mechanisms could help researchers develop therapies and improve treatment durability and patient outcomes. Subscribe to the Project Purple Podcast for more stories from the pancreatic cancer community! You can learn more about Waters lab at https://med.uc.edu/depart/cancer-biology/labs/waters-laboratory. To learn more or donate to Project Purple's mission of a world without pancreatic cancer, visit projectpurple.org.

Shock The Monkey 255 - Uncover the truth behind social media's influence and reclaim your mind in a world of chaos.Most of us are unknowingly trapped in a cycle of chaos and misinformation. In this episode, Brian Swanson and Dr. Mras explore how social media and AI distort reality, urging you to reclaim control over your mind. Discover the impact of fake news on mental health and learn practical ways to focus on what truly matters. This is a call to reject toxicity and embrace life's value. Perfect for anyone seeking clarity in today's stormy world. Listen now and start your journey back to what truly matters.FB: https://www.facebook.com/denimandpearlslive/Dr. Mras: https://michellemras.com/Denim and Pearls: https://denimandpearlslive.com/

Are you up to date on the latest clinical developments for steroidal and nonsteroidal mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved ejection fraction (HFpEF)? Credit available for this activity expires: 04/08/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/beyond-headlines-critical-look-mra-evidence-hfpef-2026a1000al7?ecd=bdc_podcast_libsyn_mscpedu

In this episode of Parallax, Dr Ankur Kalra is joined by Dr Michelle Kittleson, Professor of Medicine and Advanced Heart Failure Cardiologist at Cedars-Sinai Medical Center, for a clinically rich breakdown of her standout trial picks from the 2026 ACC Annual Scientific Sessions. Dr Kittleson brings her characteristic precision to four landmark studies spanning heart failure and atrial fibrillation. She unpacks the SPIRIT HF trial — a negative study of spironolactone in HFpEF that, she argues, does not consign the drug to the shelf — and explains why its high discontinuation rate and pandemic-era disruptions complicate the headline result. For clinicians managing cost-conscious patients, her take on spironolactone as a practical alternative to finerenone is a perspective worth hearing. The conversation turns to the CADENCE trial, a Phase 2 study of sotatercept in Group 2 pulmonary hypertension secondary to HFpEF — a phenotype Dr Kittleson treats with particular caution given the risks of misdirected pulmonary vasodilator therapy. She offers measured optimism about what these early results might mean for future treatment of HFpEF-related lung remodelling. Dr Kalra and Dr Kittleson also enter the ongoing debate around left atrial appendage closure, weighing the contrasting conclusions of the CLOSURE AF and CHAMPION AF trials against each other — and against a shared conviction that anticoagulation remains the standard of care for the vast majority of patients with atrial fibrillation. Finally, they examine the STEMI Door to Unload trial, a cautionary study in indication creep: the microaxial flow pump that proves life-saving in cardiogenic shock offered no infarct-size benefit in haemodynamically stable STEMI patients — and came with a meaningful increase in bleeding and vascular complications. Dr Kittleson also shares her stepwise outpatient algorithm for a new HFpEF diagnosis, from ruling out mimics such as cardiac amyloidosis to sequencing SGLT2 inhibitors, MRAs, GLP-1 agonists, and ARNIs based on individual patient profile. The episode closes with a discussion of her new column for NEJM Voices, where she writes on the art of medicine. Questions and comments can be sent to podcast@radcliffe-group.com and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

Please visit answersincme.com/860/101064703-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Muthiah Vaduganathan, MD, MPH and Nosheen Reza, MD, MS. In this activity, experts in cardio-kidney-metabolic syndrome (CKM) discuss emerging evidence on nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) and practical strategies for incorporating these therapies into care for patients with heart failure, with or without chronic kidney disease (CKD) or type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Specify the rationale for nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) as treatment for adult patients with HF, with or without CKD or T2D; Differentiate the risk-benefit profiles between nsMRAs and the current standard of care for the treatment of HFmrEF or HFpEF, based on the available evidence; and Recommend patient-centered, long-term care strategies to integrate nsMRAs into clinical practice for patients with HF, with or without overlapping CKD or T2D.

Join us on the Fireside Chat as we chat with the hosts of Based Camp, Malcolm and Simone! Malcolm and Simone dive deep into what it means to find success, meaning, and responsibility as an individual in the context of society. They touch on the dangers of hedonism, the importance of "delusions of grandeur," why suffering is essential, why we're not all equal, playing your role, taking on the burden of humanity, developing real confidence, having initiative, and more. We will talk about relationship dynamics, natalism, the bear meme and more!

CME credits: 0.25 Valid until: 26-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-steroidal-mras-the-nonsteroidal-mra-lens-in-hf/49198/ In this brief podcast, Drs. Maria Pabon and Robert Mentz explore the evolving role of mineralocorticoid receptor antagonism in heart failure, with emphasis on patients who appear clinically stable yet remain at elevated biologic risk. They contrast steroidal and nonsteroidal MRAs, highlighting differences in receptor selectivity, cardiac-renal distribution, and downstream anti-fibrotic and anti-inflammatory signaling. Faculty address the principle that symptom stability does not equate to disease stability, offering strategies to identify patients with HFpEF or HFmrEF who may benefit from a risk-based treatment approach.=

Today Alex discusses the Louis Theroux documentary for Netflix Inside the Manosphere with psychiatry and psychotherapy registrar Dr. Rosy Blunstone - who also leads the the Thinking Mind Substack. The Manosphere is defined as  a varied collection of onlne content made by men, for men to promote masculinity. Communities within the manosphere include mens rights activitists (MRAs), incels (involuntary celibates), Men Going their Own Way (MGTOW), pick up artists and father's right's groups. While the specifics of each group's beliefs sometimes conflict, they are generally united in the belief that society is biased against men due to the influence of feminism, and that feminists promote misandry (hatred of men). Acceptance of these ideas is described as "taking the red pill" a metaphor borrowed from the film The Matrix. Interviewed by Dr. Alex Curmi. Dr. Alex is a consultant psychiatrist and a UKCP registered psychotherapist in-training.Check out The Thinking Mind Blog on Substack: https://substack.com/home/post/p-186445029If you would like to invite Alex to speak at your organisation please email alexcurmitherapy@gmail.com with "Speaking Enquiry" in the subject line.Alex is not currently taking on new psychotherapy clients, if you are interested in working with Alex for focused behaviour change coaching , you can email - alexcurmitherapy@gmail.com with "Coaching" in the subject line.Give feedback here - thinkingmindpodcast@gmail.com Follow us here: Twitter @thinkingmindpod Instagram @thinkingmindpodcast

What does faith look like when life has broken you more than once? In this episode, Allyson sits down with Dr. Michelle Mras for a deeply moving conversation about trauma, trust, healing, resilience, and the kind of peace that comes from walking closely with God.

In this installment of CW Talks, we revisit a topic that was discussed on a panel at last year's Carbon Fiber Conference, held in Wichita, Kansas. The discussion revolved around high-rate manufacturing for aerospace, next-generation aerospace and the growing trend around urban air mobility (UAM). We recently sat down with one of the panelists, Mitchell Smith, technology leader at ST Engineering MRAS (Baltimore, Md.), to continue the conversation.

Nyheter och fördjupning från Sverige och världen. Lyssna på alla avsnitt i Sveriges Radios app.

With men's rights activism growing rapidly in India across social media platforms, in this story, we take you inside the world of MRAs. Most MRAs seem to reportedly feed into biases, exploit selective news report headlines to push certain misinformation. But do we see MRAs speaking up when men commit crimes against men? Head to our website or YouTube channel for the full video. Learn more about your ad choices. Visit megaphone.fm/adchoices

We take a closer look at the online world known as the manosphere—a loose network of communities including incels, Men Going Their Own Way (MGTOW), men's rights activists (MRAs), and pick-up artists (PUAs).These groups may look different on the surface, but they share a common core: resentment toward feminism, nostalgia for traditional masculinity, and a belief that men are the new victims of modern society. With guidance from researcher Havana Mohr-Ramirez, we unpack how these subcultures operate, where they overlap, and why they've become such powerful forces in shaping how young men see themselves and their place in the world.Drawing on insights from Laura Bates, author of Men Who Hate Women, and sociologist Ellis Cashmore, the episode examines whether the manosphere is an organized movement or something more elusive that still influences real attitudes, politics, and violence.This documentary episode goes beyond headlines and outrage to ask deeper questions about identity, belonging, and what happens when online spaces built around grievance start reshaping the world outside the screen.Text me your feedback and leave your contact info if you'd like a reply (this is a one-way text). Thanks, DavidUp The Middle PromoSupport the showShow Notes:https://outrageoverload.net/ Follow me, David Beckemeyer, on Twitter @mrblog or email outrageoverload@gmail.com. Follow the show on Twitter @OutrageOverload or Instagram @OutrageOverload. We are also on Facebook /OutrageOverload.HOTLINE: 925-552-7885Got a Question, comment or just thoughts you'd like to share? Call the O2 hotline and leave a message and you could be featured in an upcoming episodeIf you would like to help the show, you can contribute here. Tell everyone you know about the show. That's the best way to support it.Rate and Review the show on Podchaser: https://www.podchaser.com/OutrageOverload Intro music and outro music by Michael Ramir C.Many thanks to my co-editor and co-director, Austin Chen.

Please visit answersincme.com/QWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses the evolving role of mineralocorticoid receptor antagonists (MRAs) to treat patients with heart failure. Upon completion of this activity, participants should be better able to: Identify the evolving role of mineralocorticoid receptor antagonists (MRAs) to treat patients with heart failure; Evaluate clinical implications of the latest data on nonsteroidal MRAs for the treatment of heart failure and mildly reduced ejection fraction (HFmrEF) or heart failure and preserved ejection fraction (HFpEF), in the context of current standard-of-care; and Describe strategies to incorporate nonsteroidal MRAs into the treatment plans of patients with HFmrEF or HFpEF.

In this focus issue on Heart Failure in Practice, JACC Editor-in-Chief Dr. Harlan Krumholz examines how contemporary research continues to refine and at times challenge our understanding of heart failure management. This week's episode features a first-of-its-kind trial on dual therapy with SGLT2 inhibitors and MRAs, new real-world data on heart failure with improved EF, and sobering insights into what happens when foundational therapies are withdrawn. Also explored: sex-specific risks in genetic cardiomyopathies, the limitations of standard stroke prediction tools, and the case for modernizing ICD eligibility criteria. As always, the episode concludes with a synthesized summary of key takeaways for clinicians.

CME credits: 1.00 Valid until: 20-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/expert-perspectives-on-nonsteroidal-mras-and-cardiorenal-protection/32990/ Heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent a significant and growing burden for patients and the healthcare system, not only in cardiovascular medicine, but also in the context of cardio-kidney-metabolic (CKM) syndrome. Trials are underway evaluating new therapies that may offer benefits to patients with HFmrEF/HFpEF and may also have broader, multisystem effects. Tune in to stay up to date! =

CME credits: 1.00 Valid until: 20-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/expert-perspectives-on-nonsteroidal-mras-and-cardiorenal-protection/32990/ Heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent a significant and growing burden for patients and the healthcare system, not only in cardiovascular medicine, but also in the context of cardio-kidney-metabolic (CKM) syndrome. Trials are underway evaluating new therapies that may offer benefits to patients with HFmrEF/HFpEF and may also have broader, multisystem effects. Tune in to stay up to date! =

In this podcast, Ty J. Gluckman, MD, MHA, discusses the pivotal phase III FINEARTS-HF trial and how the treatment landscape is evolving for patients with heart failure (HF) with mildly reduced or preserved ejection fraction, including:The emerging role of mineralocorticoid receptor antagonists in HF careFinerenone's efficacy in reducing composite cardiovascular death and worsening HF events Why safety must be monitored, especially considering hyperkalemia riskWhere HF guideline recommendations lack compared with the current evidence PresenterTy J. Gluckman, MD, MHAMedical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)Providence Heart InstituteProvidence Health SystemPortland, OregonProgram page: https://bit.ly/448XcH0

Targeting the cardiovascular (CV)-kidney-metabolic (CKM) axis may improve outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) by addressing interconnected metabolic, kidney, and CV risks.   Credit available for this activity expires: 5/30/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002559?ecd=bdc_podcast_libsyn_mscpedu

CME credits: 0.25 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/shifting-treatment-paradigm-in-hfmrefhfpef-steroidal-and-nonsteroidal-mras/29908/ Join Drs. John McMurray and Faiez Zannad as they explore the evolving role of MRAs in heart failure management. From RALES and TOPCAT to the recent FINEARTS-HF trial, they highlight key findings that shape how steroidal and nonsteroidal MRAs are used in clinical practice. Discover how the nonsteroidal MRA finerenone is expanding treatment options for patients with HFmrEF and HFpEF.=

CME credits: 0.25 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/shifting-treatment-paradigm-in-hfmrefhfpef-steroidal-and-nonsteroidal-mras/29908/ Join Drs. John McMurray and Faiez Zannad as they explore the evolving role of MRAs in heart failure management. From RALES and TOPCAT to the recent FINEARTS-HF trial, they highlight key findings that shape how steroidal and nonsteroidal MRAs are used in clinical practice. Discover how the nonsteroidal MRA finerenone is expanding treatment options for patients with HFmrEF and HFpEF.=

Is low blood pressure hindering your heart failure treatment? How do you balance life-saving medications with hypotension? We explore the definitions, causes, and practical solutions to optimize patient care. Learn how to navigate ARNI, beta-blockers, SGLT2 inhibitors, and MRAs effectively.

In this episode, Dr. Valentin Fuster discusses a study on sodium zirconium cyclosilicate (SZC) for managing hyperkalemia in heart failure patients on mineralocorticoid receptor antagonists (MRAs) like spironolactone. While SZC effectively reduced hyperkalemia and allowed higher spironolactone doses, concerns over worsening heart failure events highlight the complex balance between treatment benefits and risks.

Our podcast show today features John Culhane and Mike Kilgarriff, partners in Ballard Spahr's Consumer Financial Services group. They discuss what supervision and enforcement will look like under a new acting director/director appointed by President Trump. This episode is a repurposing of the second half of a webinar that was produced on January 6. On January 23, we released the first half of the webinar, which consisted of Alan Kaplinsky's “fireside chat” with Kathy Kraninger, the former Director of the CFPB during Trump 1.0., linked here. With respect to supervision, we consider, among others, the following issues with respect to the CFPB's leadership under Trump 2.0: (a) Will it be business as usual or more relaxed? (b) Will it focus on compliance with the Federal consumer financial services laws and less on UDAAP? (c) Will there be reduced staffing and fewer exams? (d) Will there be fewer PAAR letters and more use of MRAS and MRIAs? With respect to enforcement, we consider, among others, the following issues with respect to the CFPB's leadership under Trump 2.0: (a) Will there be an exhaustive review of all existing investigations and lawsuits and a dismissal of those which involve “regulation by enforcement” or “pushing the envelope”? (b) Will they focus more on fraud and scams and less on UDAAP? (c) What position will they take on whether the CFPB has been unlawfully funded because the Federal Reserve Banks have had no combined earnings since September 2022? Alan Kaplinsky, Senior Counsel and former chair for 25 years of the Consumer Financial Services Group, hosts the discussion.

CME credits: 1.25 Valid until: 10-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/elevating-hf-care-with-ns-mras-the-future-is-now/30065/ Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.

CME credits: 1.25 Valid until: 10-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/elevating-hf-care-with-ns-mras-the-future-is-now/30065/ Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.

CME credits: 1.25 Valid until: 10-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/ns-mras-and-biomarkers-the-nt-probnp-connection/30064/ Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.

CME credits: 1.25 Valid until: 10-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/ns-mras-and-biomarkers-the-nt-probnp-connection/30064/ Discover the transformative potential of nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs) in optimizing care for patients with the Cardiovascular-Kidney-Metabolic syndrome. Emerging data presented at EASD, HFSA, ASN and AHA, highlight their ability to improve cardiorenal outcomes in the spectrum of the Cardiovascular-Kidney-Metabolic syndrome. By integrating ns-MRAs into individualized treatment plans, healthcare professionals can offer their patients advanced care backed by cutting-edge research.

The FiltrateJoel TopfSwapnil HiremathAC GomezJordy CohenNayan AroraSpecial Guest Brendon NuenEditing bySimon Topf and Nayan AroraShow NotesFINEARTS-HF in NEJM FINEARTS Kidney outcomes in JACCFINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes in Nature Medicine discussion in NephJC BARACH-D: Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial (Nature Medicine)Live Freely Filtered at KidneyWkSwapnil comes out as a SpiroStan post to NephJC TOPCATTOPCAT primary publication TOPCAT North American results TOPCAT funny business explained AHA/ACC/HFSA Heart Failure Guidelines (PDF)SGLT2i are 2aMRA are a 2bARBs are a 2bARNI are a 2bClinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to SpironolactoneKansas city cardiomyopathy questionnaire in patients with CKD without a diagnosis of heart failure: https://pubmed.ncbi.nlm.nih.gov/21187260/GFR slope with steroidal MRAs in HF: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2635Why Has it Been Challenging to Modify Kidney Disease Progression in Patients With Heart Failure? (JACC)Tubular SecretionsSwap: Disclaimer on Apple TVAC: Duo Lingo Plushy (Amazon)Nayan: The Puzzle BoxJordy: Project Hail MaryBrendon has a podcast, The Kidney Compass with Shikha Wadhwani. And he recommends singer-songwriter, Maggie Rogers (YouTube)Joel: The Singularity Is Nearer: When We Merge with AI by Ray KurzweilClosing music, Tim Yau with The Kidney Connection

Please visit answersincme.com/YTP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cardiology and nephrology discuss the latest evidence and guidance on the use of nonsteroidal mineralocorticoid receptor antagonist (MRA) for the treatment of cardio-renal-metabolic conditions. Upon completion of this activity, participants should be better able to: Identify patients with type 2 diabetes (T2D) who are at high risk for chronic kidney disease (CKD) progression and cardiovascular events; Outline the clinical implications of updated CKD guidelines regarding the use of nonsteroidal MRA therapy in patients with T2D and CKD; and Describe the latest evidence on the use of nonsteroidal MRA therapies in individuals with cardio-renal-metabolic conditions.

On today's Rantzerker Karen, Alison and Brian will be continuing to look at the latest from Jubilee which once again pits MRAs against feminists. Are women really oppressed? Does killing your unborn child equate to true freedom? Should men just cry more? Should we just tear down the concept of sex altogether? Join us at 4pm Eastern!

On today's Rantzerker Karen, Alison and Brian will be continuing to look at the latest from Jubilee which once again pits MRAs against feminists. Are women really oppressed? Does killing your unborn child equate to true freedom? Should men just cry more? Should we just tear down the concept of sex altogether? Join us at 12pm Eastern!

On today's Rantzerker Karen, Alison and Brian will be continuing to look at the latest from Jubilee which once again pits MRAs against feminists. Are women really oppressed? Does killing your unborn child equate to true freedom? Should men just cry more? Should we just tear down the concept of sex altogether? Join us at 12pm Eastern!

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Which MRA to use in which heart failure patient Managing electrical storm Mythbusters: garlic protects from the heart Host: Perry Elliott Guests: Carlos Aguiar, Sana Al-Khatib, Rudolf de Boer Want to watch that episode? Go to: https://esc365.escardio.org/event/1792 Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Sana Al-Khatib and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: direct research funding from European Research Council (ERC), Netherlands Heart Foundation, Fondation leDucq, Netherlands Organization for Scientific Research. Research funding to department or institution: AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, NovoNordisk. Direct fees from Abbott, AstraZeneca, Cardior Pharmaceuticals GmbH, NovoNordisk, Roche Diagnostics. Fees to department or institution: NovoNordisk. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

On today's Rantzerker Karen, Alison and Brian will be looking at the latest from Jubilee which once again pits MRAs against feminists. Are women really oppressed? Does killing your unborn child equate to true freedom? Should men just cry more? Should we just tear down the concept of sex altogether? Join us at 1pm Eastern!

MRAs in HF with renal dysfunction, coronary autoregulation, the hubris of US doctors, NSTEMI in older patients, survival after STEMI, and new leaders at JACC are discussed by John Mandrola, MD. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Combined analysis (Matsumoto) II Coronary artery autoregulation with increasing stenosis NEJM Paper https://www.nejm.org/doi/full/10.1056/NEJMc2402216 III RECOVER IV Trial Gregg Stone, MD Tweet https://x.com/GreggWStone/status/1803583552354742416 DANGER-Shock Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2312572 Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key https://www.medscape.com/viewarticle/1000659 IV NSTEMI Elderly Main Paper Datamethods https://discourse.datamethods.org/t/random-vs-fixed-effects-meta-analysis/7361 O'Fee Paper https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785560 V MI Survival Danish Paper https://doi.org/10.1016/j.jacc.2024.04.025 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback, statin eligibility and Yogi Berra, evidence-based medicine and heterogenous treatment effects, and MRAs in HF are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Listener Feedback ASPIRE AF https://classic.clinicaltrials.gov/ct2/show/NCT03968393 Butala paper: Stroke After TAVR With and Without EPD https://www.ahajournals.org/doi/abs/10.1161/CIRCINTERVENTIONS.123.013697 PROTECTED TAVR Heuts meta-analysis: EPD During TAVR https://heart.bmj.com/content/110/11/757 II. Statin Eligibility JAMA-IM: Data Analytic Choices and Predicting Vascular Events https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2819821 Zeraatker Specification Analysis Paper https://doi.org/10.1016/j.jclinepi.2024.111278 PCE https://www.mdcalc.com/calc/3398/ascvd-atherosclerotic-cardiovascular-disease-2013-risk-calculator-aha-acc III. Heterogenous Treatment Effect Weisberg and Dailey-Higgs DANISH IV. Heart Failure and MRAs  RALES https://www.nejm.org/doi/full/10.1056/NEJM199909023411001 EMPHASIS https://www.nejm.org/doi/full/10.1056/NEJMoa1009492 Combined analysis (Matsumoto) You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This is a free preview of a paid episode. To hear more, visit www.louiseperry.co.ukMy guest today is Cassie Jaye, a filmmaker best known for the hugely controversial 2016 documentary 'The Red Pill' which followed Cassie's journey from feminism to becoming (partially) persuaded by men's rights activism. We spoke about how she feels about the film – and about MRAs – eight years on.In the extended part of the episode, we also spoke about…

In the sequel to last week's episode, we are back with Dr. Jonathan Davis, Director of the Heart Failure program from San Francisco General. We continue our tour of GDMT for HF, by covering SGLT2-i, MRAs, as well as some AKI and outpatient considerations. This is part 1 of 2 parts which will cover an overview of GDMT medications, and dive into Beta-blockers and ARNIs. Part 2 to come out next week! | 00.33 - Previously on Booster Shots | | 01.31 - Chapter 3: SGLT2-i | The now famous EMPA-REG OUTCOME trial [NEJM 2015] Empagliflozin in HFpEF (not discussed in this episode [NEJM 2021] | 04.24 - Chapter 4: MRAs | RALES trial demonstrating benefit in Morbidity/Mortality [NEJM 1999] | 10.04 - Organizing follow up | | 11.51 - Issues with AKI | | 15.10 - Some fun questions about Fun questions | | 16.54 - Summary of All The Things! | [The appearance of external hyperlinks does not constitute endorsements by UCSF of the linked websites, or the information, products, or services contained therein. UCSF does not exercise any editorial control over the information found therein, nor does UCSF make any representation of their accuracy or completeness. All information contained in this episode are the opinions of the respective speakers and not necessarily the views their respective institutions or UCSF, and is only provided for information purposes, not to diagnose or treat.] Music by Amit Apte. Medical Heart Vectors by Vecteezy

A deep dive into the manosphere, with the scholar who knows it best, Louis Bachaud. The manosphere is a constellation of 5 loosely affiliated communities, including pick-up artists (PUAs), men's rights activists (MRAs), "Men Going Their Own Way" (MGTOW), incels (the "Black Pill" communiy), and the "Red Pill" community. Louis details the history of the manosphere, describes the current factions and their differences, and guides us through their use and misuse of science, especially evolutionary psychology. The episode opens with a systematic critique of the manosphere, and the interview starts around 34 minutes in. Enjoy. Recommended background, especially for critiques of the manosphere: - Bachaud, L., & Johns, S. E. (2023). The use and misuse of evolutionary psychology in online manosphere communities: The case of female mating strategies. Evolutionary Human Sciences, 5, e28.  For the size and direction of sex differences, see: - Archer, J. (2019). The reality and evolutionary significance of human psychological sex differences. Biological Reviews, 94(4), 1381-1415.  - Stewart-Williams, S., Butler, C. A., & Thomas, A. G. (2017). Sexual history and present attractiveness: People want a mate with a bit of a past, but not too much. The Journal of Sex Research, 54(9), 1097-1105.  - Schmitt, D. P. (2005). Sociosexuality from Argentina to Zimbabwe: A 48-nation study of sex, culture, and strategies of human mating. Behavioral and Brain sciences, 28(2), 247-275.  - Buss, D. M. (1989). Sex differences in human mate preferences: Evolutionary hypotheses tested in 37 cultures. Behavioral and brain sciences, 12(1), 1-14.  For extra-pair paternity: - Wolf, M., Musch, J., Enczmann, J., & Fischer, J. (2012). Estimating the prevalence of nonpaternity in Germany. Human Nature, 23, 208-217.  - Anderson, K. (2006). How well does paternity confidence match actual paternity? Evidence from worldwide nonpaternity rates. Current anthropology, 47(3), 513-520. - Bellis, M. A., Hughes, K., Hughes, S., & Ashton, J. R. (2005). Measuring paternal discrepancy and its public health consequences. Journal of Epidemiology & Community Health, 59(9), 749-754.  For age gaps: - Conroy-Beam, D., & Buss, D. M. (2019). Why is age so important in human mating? Evolved age preferences and their influences on multiple mating behaviors. Evolutionary Behavioral Sciences, 13(2), 127.  - Antfolk, J., Salo, B., Alanko, K., Bergen, E., Corander, J., Sandnabba, N. K., & Santtila, P. (2015). Women's and men's sexual preferences and activities with respect to the partner's age: Evidence for female choice. Evolution and Human Behavior, 36(1), 73-79.  - Buunk, B. P., Dijkstra, P., Kenrick, D. T., & Warntjes, A. (2001). Age preferences for mates as related to gender, own age, and involvement level. Evolution and Human Behavior, 22(4), 241-250.

Feminists like to accuse men in general, especially men in the men's rights movement, of basing their values and intentions on controlling & violent impulses & ideology. In the past, when MRAs have documented evidence of female behavior that constitutes a serious men's issue, feminists have accused those maintaining the documentation of stalking, harassment, and threatening women just for having that documentation. So what are they doing with the “Are we dating the same guy” website?

In evaluating Michael Flood's army of strawman arguments, we've run into a consistent problem with his answers. He seems to think Australia is representative of the world. This week, we're going to examine his arguments about filicides, and look at another data set for comparison. Let's see how Flood's claims hold up.

It came from the manosphere. . . In part 1 we learn about pickup artists, or PUAs — a group of men who've designed manipulative strategies in an attempt to attract women. In part 2, we explore the community of men's rights advocates, or MRAs — a group that feels men are the oppressed gender. The Sad Girls were not a fan of either. lolwtfbbq ig: @sadgap.podcast / @misandristmemes / @txgothgf / music producer @iamjonnibrooks.eth

The following question refers to Section 7.2 of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. The question is asked by Cleveland Clinic internal medicine resident and CardioNerds Intern Akiva Rosenzveig, answered first by UPMC Harrisburg cardiology fellow and CardioNerds Academy House Faculty Leader Dr. Ahmed Ghoneem, and then by expert faculty Dr. Randall Starling. Dr. Starling is Professor of Medicine and an advanced heart failure and transplant cardiologist at the Cleveland Clinic where he was formerly the Section Head of Heart Failure, Vice Chairman of Cardiovascular Medicine, and member of the Cleveland Clinic Board of Governors. Dr. Starling is also Past President of the Heart Failure Society of America in 2018-2019. Dr. Staring was among the earliest CardioNerds faculty guests and has since been a valuable source of mentorship and inspiration. Dr. Starling's sponsorship and support was instrumental in the origins of the CardioNerds Clinical Trials Program.  The Decipher the Guidelines: 2022 AHA / ACC / HFSA Guideline for The Management of Heart Failure series was developed by the CardioNerds and created in collaboration with the American Heart Association and the Heart Failure Society of America. It was created by 30 trainees spanning college through advanced fellowship under the leadership of CardioNerds Cofounders Dr. Amit Goyal and Dr. Dan Ambinder, with mentorship from Dr. Anu Lala, Dr. Robert Mentz, and Dr. Nancy Sweitzer. We thank Dr. Judy Bezanson and Dr. Elliott Antman for tremendous guidance. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. Question #27 Which of the following sentences regarding diuretics in the management of heart failure is correct? A In HF patients with minimal congestive symptoms, medical management with diuretics alone is sufficient to improve outcomes. B Prescribing a loop diuretic on discharge after a HF hospitalization may improve short term mortality and HF rehospitalization rates. C The combination of thiazide (or thiazide-like) diuretics with loop diuretics is preferred to higher doses of loop diuretics in patients with HF and congestive symptoms. D The maximum daily dose of furosemide is 300 mg. Answer #27 Explanation Choice B in correct. The guidelines give a Class 1 recommendation for diuretics in HF patients who have fluid retention to relieve congestion, improve symptoms, and prevent worsening heart failure. Recent data from the non-randomized OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry revealed reduced 30-day all-cause mortality and hospitalizations for HF with diuretic use compared with no diuretic use after hospital discharge for HF. Choice A is incorrect. With the exception of mineralocorticoid receptor antagonists (MRAs), the effects of diuretics on morbidity and mortality are uncertain. As such, diuretics should not be used in isolation, but always combined with other GDMT for HF that reduce hospitalizations and prolong survival. Choice C is incorrect. The use of a thiazide or thiazide-like diuretic (e.g., metolazone) in combination with a loop diuretic inhibits compensatory distal tubular sodium reabsorption, leading to enhanced natriuresis. In a propensity-score matched analysis in patients with hospitalized HF, the addition of metolazone to loop diuretics was found to increase the risk for hypokalemia, hyponatremia, worsening renal function, and mortality, whereas use of higher doses of loop diuretics was not found to adversely affect survival. The guidelines recommend that the addition of a thiazide (e.g., metolazone) to treatment with a loop diuretic should be reserved for patients who do not respond to moderate- or high-dose loop diuretics to minimize electrolyte abnormalities (Class...

Michelle Mras is an award-winning, internationally recognized inspirational speaker, published #1 Best Selling Author, intuitive leader, wife, and mother who has been stirring audiences and individuals to action through her compelling message of self-leadership, resilience, and living a life of intention. Michelle's infectious presentations and coaching inspire her clients to rise above negative self-talk to reclaim their inner grit. Michelle encourages you to be your best version every day and live unapologetically. Her fiery spirit and passion drive her to candidly share the key moments that transformed her into the irresistible force she is today. This episode is titled “Be The Best You… Unapologetically!” because Michelle empowers people to be your best version every day and to always live unapologetically. Jr and Michelle take a deep dive into how to be the best version of yourself by identifying your true gifts and deep desires. If all business leaders truly served others by leading with their true gifts, the world can become a better place. Michelle encourages you to be you and to never apologize for who you truly are! In this episode, business strategist and consultant, JR Spear, will teach you how to become the best version of yourself by being your most authentic and true self. Pull up a seat because this is a conversation you do not want to miss! Learn more about Michelle and her writing at www.MichelleMras.com. Connect with Business Leaders Network www.businessleadersnetworking.com    grow@businessleadersnetworking.com

Amy is joined by Dr. Srimati Basu to discuss her book The Trouble With Marriage: Feminists Confront Law and Violence in India and explore the complicated gender politics behind divorce.Srimati Basu is a Professor of Gender and Women's Studies and Anthropology, and a member of the Committee on Social Theory. She serves as the President of the Association for Feminist Anthropology, 2021-2023. Srimati has an Interdisciplinary Ph.D. from Ohio State University in Cultural Studies/ Anthropology/ Women's Studies, and her teaching, research and community work interests include Global Feminisms, Law, Gender-Based Violence, Social Movements, Feminist Methodologies, and Masculinities. At present, she is writing a monograph on anti-feminist men's rights groups, following a 2013-14 Fulbright Fellowship to conduct fieldwork with MRAs across Indian cities. She has recently begun a research project on Indian women private detectives with fellowships from National Endowment for Humanities/ American Institute of Indian Studies and from Sisters in Crime.

We demystify primary aldosteronism, MRAs (mineralocorticoid receptor antagonists), non-steroidal MRAs, and how to recognize and treat renovascular hypertension with nephrologist/hypertension expert, Dr. Matt Luther (@DrJMLuther) as part of the NephMadness  PodCrawl 2023. Fill out a bracket for NephMadness and check out all eight NephMadness PodCrawl participants at NephMadness.com/podcrawl (list below) and the MRA region write-up by Micah Schub (@AcidBassMD). The Curbsiders gets the skinny on mineralocorticoid receptor antagonists Core IM will be covering Kidney Transplant in their classic Five Pearl format The CardioNerds will be covering the effect of Heart Failure Devices on Kidney Health Freely Filtered will try to understand thrombotic microangiopathy ISN Global Kidney Care goes deep on IgA nephropathy The Cribsiders look at transitions, first the Pediatrics to Adult nephrology transition and then from living to death with palliative nephrology  Fellow on Call will be covering Onconephrology And finally, The Nephron Segment looks at Transgender Health and CKD Claim free CME for this episode at curbsiders.vcuhealth.org! Episodes | Subscribe | Spotify | YouTube | Mailing List | Contact | Swag | CME Show Segments Intro Diagnosis and Management of Primary Aldosteronism (PA) MRAs vs non-steroidal MRAs (mineralocorticoid receptor antagonists) NephMadness MRA region picks Renovascular Hypertension Outro Credits Writer and Producer: Matthew Watto MD Show Notes: Matthew Watto MD Cover Art & Infographic: Matthew Watto MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Leah Witt MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: J. Matthew Luther MD Sponsor: Locumstory Get a comprehensive view of locums, and decide if it;s right for you, at locumstory.com Sponsor: indeed Visit indeed.com/internalmedicine to start hiring now.